Equine Botulinum Neurotoxin G Immune FAB2
- Generic Name
- Equine Botulinum Neurotoxin G Immune FAB2
- Brand Names
- BAT
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 943578J0XG
- Background
Equine Botulinum Neurotoxin G Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype G. It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and p...
- Indication
Equine Botulinum Neurotoxin G Immune FAB2 is indicted for use in documented or suspected exposure to botulinum toxin serotype G in adults and pediatric patients [FDA Label].
- Associated Conditions
- Symptomatic Botulism, Symptomatic Botulism caused by Clostridium botulinum serotype G
- Associated Therapies
- -
A Clinical Study of Bacillus Coagulans in Acute Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2024-09-13
- Last Posted Date
- 2024-09-13
- Lead Sponsor
- Yamin Fan
- Target Recruit Count
- 508
- Registration Number
- NCT06593834
Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants with Steroid-Refractory Acute Graft Versus Host Disease
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- medac GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT06075706
- Locations
- 🇫🇷
CHU de Bordeaux - Hopital des Enfants, Bordeaux, France
🇫🇷CHU Grenoble Alpes - Hopital Couple Enfant (HCE), La Tronche, France
🇫🇷Centre Hospitalier Universitaire de Lille CHU Lille - Hopital Jeanne de Flandre HJF, Lille, France
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Meiji Seika Pharma Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT05905055
- Locations
- 🇯🇵
Meiji Research Site, Nankoku, Kochi, Japan
PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB
- Conditions
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- BioVersys AG
- Target Recruit Count
- 35
- Registration Number
- NCT05685615
- Locations
- 🇭🇺
University of Debrecen Clinical Center, Debrecen, Hungary
🇭🇺University Educational Hospital, Miskolc, Hungary
🇭🇺Fejer County St. Gyorgy University Teaching Hospital, Szekesfehervar, Hungary
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT05639647
- Locations
- 🇮🇳
Sahaydri Super Speciality Hospital, Nagar road, Pune, Maharashtra, India
🇪🇸Hospital Universitario HM Monteprincipe, Boadilla del Monte, Madrid, Spain
🇺🇸Rady Children's Hospital, San Diego, California, United States
Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2021-09-05
- Target Recruit Count
- 21
- Registration Number
- NCT04954014
- Locations
- 🇪🇸
Hospital Universitario Reina Sofía, Córdoba, Córdona, Spain
Treatment of Steroid-Refractory Acute Graft-versus-host Disease with Mesenchymal Stromal Cells Versus Best Available Therapy
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- medac GmbH
- Target Recruit Count
- 210
- Registration Number
- NCT04629833
- Locations
- 🇫🇷
Centre Hospitalier Universitaire (CHU) Amiens-Picardie - Hopital Sud, Amiens, France
🇫🇷CHU Jean Minjoz, Besancon, France
🇫🇷CHU de Nantes - Hotel Dieu, Nantes, France
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
- Conditions
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2023-03-03
- Target Recruit Count
- 517
- Registration Number
- NCT04366908
- Locations
- 🇪🇸
Hospital Universitario Reina Sofía, Cordoba, Spain
Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria
- Conditions
- Interventions
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT03580044
- Locations
- 🇨🇳
The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
🇨🇳Hunan Province People's Hospital, Changsha, Hunan, China
🇨🇳The First Hospital of Kunming, Kunming, China
GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)
- Conditions
- Interventions
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT02666287
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.